Suchergebnisse - "Miranda, Roberto"

PubPharm (14)

1

Chimeric antigen receptor T-cell therapy's role in antiphospholipid syndrome : a case report

enthalten in: British journal of haematology | 2020

von Schmelz, J. | Navsaria, L. | Goswamy, R. | +3

2

Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma

enthalten in: British journal of haematology | 2017

von Chihara, D. | Westin, J. | Miranda, R. | +14

3

P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma

enthalten in: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc | 2017

von Wang, X. | L Jeffrey Medeiros | Bueso-Ramos, C. | +9

4

Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2016

von Xu-Monette, Z. | Deng, Q. | Manyam, G. | +31

5

Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

enthalten in: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc | 2015

von Xu-Monette, Z. | Dabaja, B. | Wang, X. | +30

6

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma

enthalten in: British journal of haematology | 2015

von Chihara, D. | Pro, B. | Loghavi, S. | +16

7

Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2014

von Ok, C. | Li, L. | Xu-Monette, Z. | +27

ErratumIn: Clin Cancer Res. 2014 Sep 15;20(18):4974 Dybaer, Karen [corrected to Dybkaer, Karen]

8

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures : a report from The International DLBCL Rituximab-CHOP Consortium Program

enthalten in: Blood | 2013

von Hu, S. | Xu-Monette, Z. | Tzankov, A. | +34

9

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature : a report from the International DLBCL Rituximab-CHOP Consortium Program Study

enthalten in: Blood | 2013

von Hu, S. | Xu-Monette, Z. | Balasubramanyam, A. | +32

CommentIn: Blood. 2013 Apr 4;121(14):2582-3. - PMID 23557969

10

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status : a report from an International DLBCL rituximab-CHOP Consortium Program Study

enthalten in: Haematologica | 2013

von Visco, C. | Tzankov, A. | Xu-Monette, Z. | +33